PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma
Oncology Research · 2025
DOI: 10.32604/or.2025.067628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Fangyuan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking Uni…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neoplastic Stem Cells. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Liver cancer stem cells (LCSCs) are recognized as pivotal drivers of hepatocellular carcinoma (HCC) progression; however, the molecular mechanisms maintaining their stem-like phenotype remain largely unresolved. This work investigates the role of prefoldin subunit 6-like protein (PFDN6L) in shaping LCSC traits and promoting or restraining HCC progression.
Methods
PFDN6L, a cytoskeleton-associated chaperone, was studied using multiple in vitro assays-cell growth evaluation, cell cycle profiling, and spheroid culture-alongside analyses of stemness-associated markers (SOX2, CD133, CD44). Tumorigenic capacity was assessed in xenograft mouse models, and signaling pathway interrogation was performed to define underlying mechanisms.
Results
In patient samples, higher PFDN6L expression correlated with improved survival outcomes. Forced expression of PFDN6L induced G2/M arrest, diminished sphere formation, and reduced pluripotency marker expression, whereas knockdown accelerated in vivo tumor formation. Mechanistic experiments demonstrated that PFDN6L suppresses malignancy by simultaneously dampening AKT and ERK1/2 activation, thereby impairing oncogenic signaling cascades.
Conclusion
PFDN6L acts as a negative regulator of LCSC-driven tumorigenesis. Its dual blockade of AKT and ERK pathways forms the mechanistic basis of its tumor-suppressive action, supporting its potential as a prognostic biomarker and therapeutic target in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, 650118, China.
- Shenzhen Baoan Women's and Children's Hospital, Shenzhen, 518100, China.
- Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
Zitieren
APA
Li, F., Hu, X., Gao, X., Liu, L., Li, T., He, D., Cheng, J., Ma, X., Li, L., Ge, C., & Yao, H. (2025). PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma. Oncology Research. https://doi.org/10.32604/or.2025.067628
Vancouver
Li F, Hu X, Gao X, Liu L, Li T, He D, et al. PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma. Oncology Research. 2025. doi:10.32604/or.2025.067628
BibTeX
@article{Li2025,
author = {Li, Fangyuan and Hu, Xiaoyuan and Gao, Xiaoge and Liu, Ling and Li, Tao and He, Dan and Cheng, Jiaxing and Ma, Xiaobiao and Li, Li and Ge, Chunlei and Yao, Hong},
title = {PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.067628}
}
EUVIMED